Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication

2009 ◽  
Vol 169 (1) ◽  
pp. 51-55 ◽  
Author(s):  
Krasimira Halacheva ◽  
Svetlana Dimova ◽  
Todor Tolev ◽  
Dimo Dimov ◽  
Maria Nikolova
Keyword(s):  
Anticardiolipin Antibodies ◽  
Neuroleptic Medication ◽  
Schizophrenic Patients

75 – Neuroleptic medication affects global dimensionality of multichannel EEG in schizophrenic patients

2008 ◽  
Vol 98 ◽  
pp. 64
Author(s):  
T.P. Waltinger ◽  
D. Lehmann ◽  
P.L. Faber ◽  
T. Koenig ◽  
K. Kochi ◽  
...  
Keyword(s):  
Neuroleptic Medication ◽  
Schizophrenic Patients ◽  
Multichannel Eeg

Sodium Valproate and Tardive Dyskinesia

1978 ◽  
Vol 133 (1) ◽  
pp. 82-82 ◽  
Author(s):  
Alan C. Gibson
Keyword(s):  
Tardive Dyskinesia ◽  
Sodium Valproate ◽  
Neuroleptic Medication ◽  
Schizophrenic Patients

SummaryTwenty-five schizophrenic patients with tardive dyskinesia were given 600 mgs sodium valproate daily with their neuroleptic medication. After one month there was no change in their signs, as judged by a panel of nine viewing films of them taken before and at the end of this treatment.

Ideal and Reality of Neuroleptic Relapse Prevention

1992 ◽  
Vol 161 (S18) ◽  
pp. 133-139 ◽  
Author(s):  
Werner Kissling
Keyword(s):  
Protective Effect ◽  
Patient Care ◽  
Relapse Prevention ◽  
Psychiatric Hospitals ◽  
Shock Therapy ◽  
Neuroleptic Medication ◽  
Psychosocial Therapy ◽  
Schizophrenic Patients ◽  
Hospital Stays

The discovery of neuroleptics some 40 years ago brought about a revolution in the treatment of schizophrenia. Until then, schizophrenic patients were primarily treated with various forms of coma and shock therapy, and many were permanently confined in psychiatric hospitals. With the availability of neuroleptic medication, however, hospital stays have become considerably shorter and many patients can be returned home for out-patient care. In addition, psychosocial therapy for schizophrenic psychoses could not have been effective without the protective effect of neuroleptics.

Gonadotrophin secretion abnormalities in chronic schizophrenia

1982 ◽  
Vol 12 (2) ◽  
pp. 263-273 ◽  
Author(s):  
I. N. Ferrier ◽  
P. M. Cotes ◽  
T. J. Crow ◽  
E. C. Johnstone
Keyword(s):  
Natural History ◽  
Clinical Features ◽  
Anterior Pituitary ◽  
Chronic Schizophrenia ◽  
Neuroleptic Medication ◽  
Acute Schizophrenia ◽  
Chronic Schizophrenic ◽  
Gonadotrophin Secretion ◽  
Schizophrenic Patients ◽  
Lh Secretion

SynopsisLH, FSH, PRL and testosterone were estimated by radioimmunoassay in serial venous samples from 20 male chronic schizophrenic patients, 17 age-matched controls, 3 patients in remission from acute schizophrenia, and in single samples from age–sex matched populations. LH and FSH, but not testosterone or PRL, were significantly reduced in patients with chronic schizophrenia. There was an associated reduction in the frequency, but not amplitude, of LH secretory episodes in patients with chronic schizophrenia. No abnormalities of LH secretion were detected in those patients in remission from acute schizophrenia. Fourteen of the chronic schizophrenic patients were retested at a later date with similar results, except in the case of the few patients who had been started on neuroleptic medication. Some relationships were established between hormonal secretion and the clinical features of these patients. The possible significance of these findings is discussed in the context of the complex control of gonadotrophin secretion from the anterior pituitary and the natural history and nature of chronic schizophrenia.

The Withdrawal of Benztropine Mesylate in Chronic Schizophrenic Patients

1983 ◽  
Vol 143 (6) ◽  
pp. 584-590 ◽  
Author(s):  
Linda A. Baker ◽  
L. Y. Cheng ◽  
I. B. Amara
Keyword(s):  
Placebo Group ◽  
Test Scores ◽  
Drug Group ◽  
Extrapyramidal Symptoms ◽  
Antiparkinsonian Drug ◽  
Double Blind ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Wechsler Memory Scale ◽  
Schizophrenic Patients

SummaryIn this double-blind, four-week study, 28 chronic schizophrenic patients receiving neuroleptic medication plus the antiparkinsonian drug, benztropine mesylate, were either switched to placebo or maintained on benztropine. Patients withdrawn from benztropine reliably increased their overall scores on the Wechsler Memory Scale in comparison with the drug group. Sub-test scores suggest that deficits in attention and concentration were induced by treatment with benztropine. Psychotio decompensation appeared to develop simultaneously with extrapyramidal symptoms (EPS) in some patients, but only 14.2 per cent of the placebo group experienced extrapyramidal symptoms severe enough to require resumption of benztropine therapy. It is suggested that antiparkinsonian agents should be prescribed only if and when EPS occur.

Consent to Neuroleptic Medication for Schizophrenia: Clinical, Ethical and Legal Issues

1996 ◽  
Vol 168 (5) ◽  
pp. 540-544 ◽  
Author(s):  
Clare Brabbins ◽  
Jonathan Butler ◽  
Richard Bentall
Keyword(s):  
Clinical Practice ◽  
Informed Consent ◽  
Routine Clinical Practice ◽  
Legal Issues ◽  
Legal Requirements ◽  
Neuroleptic Medication ◽  
Capacity To Consent ◽  
Adverse Side Effects ◽  
Schizophrenic Patients ◽  
Ethical And Legal Issues

BackgroundThe effects of neuroleptic medication on schizophrenic patients are both positive (reduction in symptoms) and negative (adverse side-effects). Given that altered cognitive functioning may be a feature of schizophrenia, the use of neuroleptics raises important ethical and legal issues.MethodA selective review was carried out of papers addressing ethical arguments for and against obtaining consent from schizophrenic patients, and the ethical and legal requirements which must be met for consent to occur.ResultsAlthough a balance must be met between arguments for and against obtaining consent, clinicians should seek informed consent in all but exceptional circumstances. Obtaining consent depends on the adequate presentation of information, the absence of duress and the patients' capacity to consent. Various tests of capacity to consent have been proposed.ConclusionsIt is proposed that clinicians employ a proforma to record attempts to obtain informed consent during routine clinical practice.

Treating Prodromal Episodes to Prevent Relapse in Schizophrenia

1989 ◽  
Vol 155 (S5) ◽  
pp. 123-127 ◽  
Author(s):  
Marvin I. Herz ◽  
William Glazer ◽  
Mahmud Mirza ◽  
Marcelle Mostert ◽  
Hisham Hafez
Keyword(s):  
Tardive Dyskinesia ◽  
Antipsychotic Medication ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Preliminary Results ◽  
Active Medication ◽  
Maintenance Medication ◽  
Schizophrenic Patients

Our current study compares intermittent medication with maintenance medication in the treatment of stable schizophrenic out-patients. According to the intermittent approach, known active medication is given only when the patient develops prodromal signs of relapse and until the patient restabilises. After restabilisation, medication is discontinued. The impetus for this work came as the result of our interest in finding ways to diminish the incidence of tardive dyskinesia. Many investigators believe that tardive dyskinesia is generally related to the amount of neuroleptic medication a patient has taken during his lifetime. Since it is routine for many aftercare clinics to maintain these patients indefinitely on antipsychotic medication, ways must be found to reduce the amount of medication taken by chronic schizophrenic patients. This paper will present the background ideas and preliminary studies which led to the present study and preliminary results of the present study.

Transient Recurrence of Auditory Hallucinations During Acute Dystonia

1989 ◽  
Vol 155 (1) ◽  
pp. 110-113 ◽  
Author(s):  
Leo P. W. Chiu
Keyword(s):  
Auditory Hallucinations ◽  
Psychotic Symptoms ◽  
Neuroleptic Medication ◽  
Dopaminergic Neurotransmission ◽  
Acute Dystonia ◽  
Schizophrenic Patients

Three schizophrenic patients who had transient recurrence of auditory hallucinations during acute dystonia precipitated by neuroleptic medication are reported. If it is accepted that psychotic symptoms result from dopaminergic overactivity, such phenomena suggest that acute dystonia might also have been caused by increased dopaminergic neurotransmission in these cases.

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1983 ◽  
Vol 143 (2) ◽  
pp. 151-155 ◽  
Author(s):  
C. R. Pugh ◽  
J. Steinert ◽  
R. G. Priest
Keyword(s):  
Beneficial Effect ◽  
Recent Work ◽  
Controlled Trial ◽  
Pharmacokinetic Interaction ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

SummaryA double blind, placebo controlled trial was carried out to examine the contribution of propranolol as an adjunct to neuroleptic medication in the treatment of chronic schizophrenic patients whose florid symptoms had not remitted with neuroleptic medication alone. Propranolol was shown to have a more beneficial effect than placebo, but the results were much less dramatic than those which have been described in previous studies. Recent work has shown that there may be a pharmacokinetic interaction between propranolol and neuroleptics, and this should be considered as one possible explanation of our findings.

Sign in / Sign up

Export Citation Format

Share Document